Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Aug 30;17(1):195.
doi: 10.1186/s12877-017-0600-7.

A multi-center, randomized, controlled trial to assess the efficacy of optimization of drug prescribing in an elderly population, at 18 months of follow-up, in the evolution of functional autonomy: the OPTIM study protocol

Affiliations
Randomized Controlled Trial

A multi-center, randomized, controlled trial to assess the efficacy of optimization of drug prescribing in an elderly population, at 18 months of follow-up, in the evolution of functional autonomy: the OPTIM study protocol

Virginie Dauphinot et al. BMC Geriatr. .

Abstract

Background: Pharmacotherapy is necessary for the management of many diseases which number increased with aging. However, potentially inappropriate prescriptions and polymedication increases iatrogenic risks and can lead to adverse events. To limit the consequences of potentially harmful prescriptions, optimization of drug prescribing is a major stake of improving quality and safety of care in the elderly. The purpose of the OPTIM study is to study the impact of the optimization of drug prescribing on the evolution of functional autonomy at 18 months of follow-up.

Methods: A multicenter, open-label, Randomized Controlled Trial was designed to assess the impact of an optimization program of drug prescribing consisting in a clinical medication review by a pharmacist, in collaboration with specialist physician of the geriatric/memory center and the referent physician, on the evolution of functional autonomy level, measured during 18 months of follow-up. The study will include 302 elderly outpatients visiting geriatric and memory centers, randomly distributed in one of the two parallel groups. One group will benefit of the intervention, while the other will be considered as control group. The effect of the intervention on evolution of the level of autonomy function, defined with repeated measures, will be estimated in a generalized linear mixed model. The intervention will be considered significant if the interaction between time and the study group is significant. Secondary analysis will be conducted to assess the impact of the intervention on secondary clinical outcomes.

Discussion: The "OPTIM" program should enable optimization of drug prescribing in elderly patients and therefore slow or prevent progression to loss of functional autonomy. It should also help to strengthen collaboration between the hospital team of geriatric/neurologist, the pharmacist and the private practice who are all involved in caring for the patient's health. The benefits for the patient are thus optimizing its medical management by linking health professionals met during his care pathway. In addition, pharmaceutical recommendations sent to referent physicians should help raise awareness of the prescription of drugs in these patients.

Trial registration number clinicaltrials: NCT02740764.

Keywords: Daily living activities; Elderly; Inappropriate prescribing; Neurocognitive disorders; Randomized controlled trial.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Ethics approvals were obtained with three committees as required in France: the Committee for the protection of persons concerned (CPP), the Advisory Committee on Information Processing in Material Research in the Field of Health, and the National Commission for Data Protection and Liberties (CNIL). The latest agreement was obtained the 29th march 2016, allowing starting the study. No consent to participate was required since the study was conducted in routine care, but patients may refuse to participate. The study enrolment began in May 2016.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Similar articles

Cited by

References

    1. Spinewine A, Schmader K, Barber B, et al. Appropriate prescribing in elderdly people: how well can it be measured and optimised? Lancet. 2007;370:173–184. doi: 10.1016/S0140-6736(07)61091-5. - DOI - PubMed
    1. Ferchichi S, Antoine V. Le bon usage du médicament chez la personne âgée. Rev Med Interne. 2004;25:582–590. doi: 10.1016/j.revmed.2004.02.027. - DOI - PubMed
    1. Mannese C, Derkx F, de Ridder M, Man in’t Veld A, van der Cammen T. Adverse drug reactions in the elderdy patients as contributing factor for hospitalisation admission: cross sectionnal study. BMJ. 1997;315:1057–1058. doi: 10.1136/bmj.315.7115.1057. - DOI - PMC - PubMed
    1. Field TS, Gurwitz JH, Avorn J, et al. Risk factors for adverse drug events among nursing home residents. Arch Int Med. 2001;161(13):1629–1634. doi: 10.1001/archinte.161.13.1629. - DOI - PubMed
    1. Lindblad C, Hanlon J, Gross C, et al. Clinically important drug-disease interactions and their prevalence in older adults. Clin Ther. 2006;28(8):1133–1143. doi: 10.1016/j.clinthera.2006.08.006. - DOI - PubMed

Publication types

Associated data

LinkOut - more resources